The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study.
 
Juergen Wolf
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Ignyta; Janssen; Lilly; Loxo; MSD; Novartis; Pfizer; Roche; Seagen; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Ignyta; Janssen; Lilly; Loxo; MSD; Novartis; Pfizer; Roche; Seagen; Takeda
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Dracen; Eisai; EMD Serono; GlaxoSmithKline; Merck; Novartis; Sanofi; Shionogi; Xilio Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Harry J.M. Groen
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly; Novartis (Inst); Roche/Genentech (Inst)
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Isabelle Gilloteau
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Sylvie Le Mouhaer
Employment - Novartis
 
Can Cai
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Andrea Chassot-Agostinho
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Maria Reynolds
Research Funding - RTI Health Solutions (Inst)
 
Dawn Odom
Research Funding - RTI Health Solutions (Inst)
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Apollomics; Boehringer Ingelheim; Daichii Sankyo; Daichii Sankyo; EMD Serono/Merck; EMD Serono/Merck; Novartis; Tarveda Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)